1. 首页
  2. 产品目录
  3. 标准品
  4. 药品杂质对照品
  5. 布地奈德杂质

布地奈德杂质09对照品

(8S,9S,10R,11S,13S,14S,16R,17S)-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-16-yl butyrate （订货以CAS编码或英文名称为准）

创赛科技提供的所有产品仅用于科研等非医疗用途，非药品不可食用，不可用于人体或动物的临床诊断和治疗,我们不为个人提供产品及服务。如您需要产品COA等资料，可至下方“质量控制”中下载
编号：PC70493
分子式：C25H34O7
CAS号：113930-13-5
分子量：446.53
储存条件：-20°C
申请试用
货号 品牌 规格 纯度/含量 标准价 优惠价 库存货期 数量 购买
PC70493-10mg Medlife 10mg
≥95%
 待询 登录后可见
PC70493-25mg Medlife 25mg
≥95%
 待询 登录后可见
PC70493-50mg Medlife 50mg
≥95%
 待询 登录后可见
PC70493-100mg Medlife 100mg
≥95%
 待询 登录后可见
中文名称： 布地奈德杂质I
中文别名： 布地奈德杂质I;布地奈德杂质I(EP) 标准品;布地奈德EP杂质I
英文名称： (8S,9S,10R,11S,13S,14S,16R,17S)-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-16-yl butyrate
英文别名： Imp. I (EP): 11 ,17,21-Trihydroxy-3,20-dioxopregna-1,4-dien-16 -yl Butanoate;16α-Butyloxyprednisolone (Budenoside Impurity);16α-Butyloxyprednisolone (Budenoside Impurity);Budesonide Impurity I;Budesonide EP Impurity I;Budenoside Impurity I(EP);16±-Butyloxyprednisolone\n(Budenoside Impurity);11β,17,21-trihydroxy-3,20-dioxopregna-1,4-dien-16α-yl butanoate
CAS号： 113930-13-5
分子式： C25H34O7
分子量： 446.53
详细描述 仅用于研发试验中鉴别、检查。113930-13-5|布地奈德杂质09对照品，制备中，详情请联系Medlife客服进行咨询。(8S,9S,10R,11S,13S,14S,16R,17S)-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-16-yl butyrate可放大生产，批量保障。
搜索质检报告(COA)
相关产品
(6aS,6bR,7S,8aS,8bS,11aR,12aS,12bS)-6b-bromo-7-hydroxy-8b-(2-hydroxyacetyl)-6a,8a-dimethyl-10-propyl-6a,6b,7,8,8a,8b,11a,12,12a,12b-decahydro-1H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-4(2H)-one
(6aR,6bS,7S,8aS,8bS,11aR,12bR)-7-hydroxy-8b-(2-hydroxyacetyl)-6a,8a-dimethyl-10-propyl-6a,6b,7,8,8a,8b,11a,12b-octahydro-1H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-4(2H)-one
2-((6aR,6bS,7S,8aS,8bS,11aR,12aS,12bS)-7-hydroxy-6a,8a-dimethyl-4-oxo-10-propyl-2,4,6a,6b,7,8,8a,8b,11a,12,12a,12b-dodecahydro-1H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-8b-yl)-2-oxoacetaldehyde
2-((6aR,6bS,7S,8aS,8bS,11aR,12aS,12bS)-7-hydroxy-6a,8a-dimethyl-4-oxo-10-propyl-1,2,4,6a,6b,7,8,8a,11a,12,12a,12b-dodecahydro-8bH-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-8b-yl)-2-oxoethyl acetate
(6aR,6bS,7S,8aS,8bS,11aR,12aS,12bS)-7-hydroxy-8b-(2-hydroxyacetyl)-6a,8a-dimethyl-10-propyl-5,6,6a,6b,7,8,8a,8b,11a,12,12a,12b-dodecahydro-1H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-4(2H)-one
(6aS,8aS,8bS,11aR,12aS,12bS)-8b-(2-hydroxyacetyl)-6a,8a-dimethyl-10-propyl-6a,8,8a,8b,11a,12,12a,12b-octahydro-1H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-4(2H)-one
(8S,9S,10R,11S,13S,14S,16R,17S)-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-16-yl butyrate
(6aR,6bS,8aS,8bS,11aR,12aS,12bS)-8b-(2-hydroxyacetyl)-6a,8a-dimethyl-10-propyl-6b,8,8a,8b,11a,12,12a,12b-octahydro-1H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxole-4,7(2H,6aH)-dione
Obatoclax (mesylate)
ABT-737